Pricing Log in Create free account
Saturday 7 November 2026 Export HYPD’s income statement to Excel — free account

Hyperion DeFi, Inc.

HYPD Healthcare Biotechnology

Hyperion DeFi, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $813,500.00, up 1,319.7% from fiscal 2024.

Revenue
+2,333.3%
EPS
+140.4%
Free cash flow
+86.8%
Total debt
+12.3%

Quarter to June 2026, against a year earlier

2.52 0.04 −1.56%
Market cap
$39.8M
P/E
0.0×
Fwd P/E
0.5×
Dividend yield
—
F-score
5/9
Altman Z
−8.37
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.64
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 5 — — — — — 1 — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 9.55%

Capital & Financial Ratios $m

Size
Market Cap 39.78
Revenue ttm 1.40
Net income ttm 6.65
Free cash flow ttm (77.17)
Net debt Q (1.20)
Valuation
P/E 0.00
Forward P/E 0.46
Price / sales 25.50 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.35
Financial health
Current ratio Q 2.34 (at or above 1.5: strong)
Debt / equity Q 0.08 (at or below 0.5: strong)
Interest coverage Q 132.62
Growth
Revenue growth Q +2,333.33% (above 0%: growing)
Operating income growth Q +471.20% (above 0%: growing)
EPS, this year +174.47% (at or above 15%: strong)
EPS, next year A −65.43% (below 0%: weak)
Revenue, next year A +182.73% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +84.68% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 24.6×, against a ten-year median of 9.7×; over the ten years it ranged from 2.8× in 2022 to 2,212× in 2024.
P/S against its own 10 years 58.95%
10-year low 10-year high
P/B against its own 10 years 1.53%
10-year low 10-year high
EV/Sales against its own 10 years 51.72%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 15 2 6 10
Receivables 0 0 — —
Inventory 0 — — —
Other 0 0 — —
21 3 7 13
2023 2024 2025 Q'26
Payables 2 2 0 0
ST’ Debt — 5 — 3
Other — — — —
10 16 3 6

Compound Annual Growth %

10y 5y 3y
Sales — — (61.27%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 32.85% 21.82% 33.56%

EPS $

Mar Jun Sep Dec Year
’26 0.26 0.92 — — —
’25 (1.59) (2.50) 0.05 (7.76) (9.40)
’24 (18.40) (16.80) (8.80) (16.41) (59.81)
’23 (12.00) (12.80) (14.40) (14.40) (52.80)
’22 (19.20) (17.60) (16.80) (13.60) (66.40)
’21 (16.80) (15.20) (16.80) 8.00 (39.20)
’20 (24.80) (20.00) (18.40) (13.60) (75.20)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 — 0 0 1
’24 0 0 0 0 0
’23 — — 0 0 0
’21 2 2 — 10 14
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (4) (3) (3) (4) (15)
’24 (10) (8) (6) (6) (30)
’23 (7) (5) (6) (6) (24)
’22 (8) (5) (7) (5) (25)
’21 (5) (5) (5) (6) (21)
’20 (6) (4) (2) 5 (6)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) 0 — — —
’25 (4) (3) (68) (4) (15)
’24 (10) (8) (6) (6) (30)
’23 (8) (6) (8) (6) (28)
’22 (8) (5) (7) (6) (26)
’21 (5) (6) (6) (6) (22)
’20 (6) (4) (2) 5 (7)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — 2 14 — 0 0 1 1 (16.5%) 2 6 12 +141.8%
Gross margin, % 0.00 0.00 0.00 0.00 60.00 88.57 0.00 (321.05) (6,753.75) 62.72 78.35 +62.7 pt
EBT (4) (5) (17) (21) (20) (13) (28) (27) (50) (45) 7 +32.8%
EBT margin, % 0.00 0.00 0.00 0.00 (988.50) (91.27) 0.00 (717,397.37) (86,943.11) (5,570.30) 474.88 (5,570.3) pt
Net income (4) (5) (17) (21) (20) (13) (28) (27) (50) (45) 7 +32.8%
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 7.60 42.54 0.00 0.01 0.07 0.16 0.10 n/m
Earnings (124.71) (175.20) (145.60) (117.60) (75.20) (39.20) (66.40) (52.80) (59.81) (9.40) (6.19) (25.0%)
Cash flow (113.20) (161.47) (110.64) (105.46) (24.26) (63.43) (59.69) (46.47) (36.16) (2.95) (0.99) (33.3%)
Capex (1.52) (0.35) (0.24) (0.93) (0.99) (4.92) (2.08) (7.74) (0.19) 0.00 (4.46) n/m
Free cash flow (114.72) (161.82) (110.88) (106.39) (25.25) (68.35) (61.77) (54.22) (36.35) (2.95) (5.44) (33.4%)
Book value 106.33 173.74 142.41 65.44 58.15 62.19 40.98 17.55 (15.72) 8.21 7.19 (24.8%)
Shares, m 0 0 0 0 0 0 0 1 1 5 9 +77.7%
Valuation, ×
Valuation, × P/E — — — — 0.00 0.00 — 0.00 0.00 0.00 0.00 0.0
P/S — — — — 0.00 6.58 — 6.60 169.80 21.15 25.50 40.8
P/B — — — — 8.34 5.15 — 8.80 0.00 0.43 0.35 4.5
EV/Sales — — — — 0.00 6.25 — 6.40 252.79 33.94 24.64 59.9
EV/FCF — — — — (15.00) (4.45) — (2.88) (0.48) (0.36) (0.45) (4.6)
Cash, $m
Cash, $m Operating cash flow (3) (5) (13) (19) (6) (21) (25) (24) (30) (15) (14) +18.5%
Capex 0 0 0 0 0 (2) (1) (4) 0 — (63) +18.0%
Free cash flow (3) (5) (13) (19) (7) (22) (26) (28) (30) (15) (77) +18.3%
Balance, $m
Balance, $m Working capital 3 5 17 11 15 11 23 11 (13) 5 7 +4.9%
Net debt (3) (5) (20) (14) (28) (12) (14) (6) 3 1 (1) n/m
Shareholders’ equity 3 5 17 12 15 20 17 9 (13) 41 102 +33.7%
Returns, %
Returns, % ROA (113.05) (113.04) (134.48) (121.90) (81.35) (38.98) (89.36) (91.15) (307.07) (169.57) (20.32) (56.5) pt
ROIC 0.00 0.00 0.00 0.00 0.00 (99.54) (574.56) (511.04) 0.00 (68.85) 2.73 (68.8) pt
ROE (130.70) (126.68) (157.09) (147.87) (146.20) (71.45) (148.60) (207.83) 2,432.00 (336.14) (24.63) (205.4) pt
People
People Employees — 13 24 29 34 45 41 57 14 9 — (4.5%)
Revenue/emp, $m — 0.00 0.00 0.00 0.06 0.31 0.00 0.00 0.00 0.09 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

Hyperion DeFi, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
GANX Gain Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) +27.78% (above 0%: growing) n/m +8.22% (above 0%: growing) 0.00% 0.00% Compare
SGMOQ Sangamo Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) −77.60% (below 0%: shrinking) n/m +26.21% (above 0%: growing) 100.00% (2,215.40%) Compare
LONA LeonaBio, Inc. $40.9M — (loss-making) — — n/m −142.29% (below 0%: shrinking) 0.00% 0.00% Compare
ATNM Actinium Pharmaceuticals, Inc. $40.9M 3.9× 8.4× +77,677.78% (above 0%: growing) n/m −4.91% (below 0%: shrinking) 100.00% 78.76% Compare
HYPD Hyperion DeFi, Inc. $39.8M — (loss-making) 0.5× +2,333.33% (above 0%: growing) n/m +86.82% (above 0%: growing) 100.00% 8,668.63%
DWTX Dogwood Therapeutics, Inc $39.8M — (loss-making) — — n/m +10.31% (above 0%: growing) — 0.00% Compare
EXOZ eXoZymes Inc. $38.1M — (loss-making) — — n/m −3.25% (below 0%: shrinking) — 0.00% Compare
IBO Impact Biomedical Inc. $38.0M — (loss-making) — −57.14% (below 0%: shrinking) n/m +167.72% (above 0%: growing) 66.67% (23,400.00%) Compare
ELTX Elicio Therapeutics, Inc. $37.9M — (loss-making) — (loss-making) −55.27% (below 0%: shrinking) n/m +8.77% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $40.3M — — −55.27% — +8.50% 33.34% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 5 May 2026

Ownership

Directors and executive officers, together 7.50%
Forsakringsaktiebolaget Avanza Pension 8.10%
Armistice Capital, LLC 8.00%
Avenue Capital Group 5.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Hyperion DeFi, Inc. (HYPD) Latest News

10 Sep

Impact 4 ·

13 Aug

Impact 4 · transcript
Impact 3 · · Moby transcript

12 Aug

Impact 4 · · cryptoprowl.com

16 Jul

Impact 4 · · cryptoprowl.com

22 Jun

Impact 3 · · cryptoprowl.com

18 Jun

Impact 3 · · cryptoprowl.com

15 May

Impact 4 · · Moby transcript

14 May

Impact 4 · · GuruFocus.com
Impact 4 · · The Motley Fool transcript

26 Mar

Impact 4 · · GuruFocus.com

5 Feb

Impact 4 · · 99bitcoins.com
Impact 4 ·

14 Nov

Impact 4 · · GuruFocus.comGuruFocus.comStockStoryGuruFocus.comGuruFocus.comStockStoryGuruFocus.com

29 Sep

Impact 4 · · ccn.com

27 Sep

Impact 3 · · marketwatch.com

14 Aug

Impact 4 · · GuruFocus.com

30 Jun

Impact 4 ·

17 Jun

Impact 4 · · MT Newswires

19 May

Impact 4 · · GlobeNewswire

10 Apr

Impact 4 · · GlobeNewswire

20 Mar

Impact 4 · · GlobeNewswire
Impact 3 ·

26 Feb

Impact 4 · · GlobeNewswire

24 Feb

Impact 4 · · GlobeNewswire

29 Jan

Impact 4 ·

28 Jan

Impact 4 ·

15 Jan

Impact 4 · · GlobeNewswire

6 Jan

Impact 4 ·

6 Dec

Impact 3 ·
stockrow.com/HYPD · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com